Identification of proteases employed by dendritic cells in the processing of protein purified derivative (PPD)

Mansour Mohamadzadeh*1, Hamid Mohamadzadeh2, Melissa Brammer4, Karol Sestak3 and Ronald B Luftig1

Address: 1Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, USA, 2Johannes Wolfgang Goethe Medical School, Frankfurt, Germany, 3Tulane National Primate Research Center Science, New Orleans, Louisiana, USA and 4Tulane Medical School, New Orleans, LA, USA

Email: Mansour Mohamadzadeh* - mzadeh@lsuhsc.edu; Hamid Mohamadzadeh - mzadeh@lsuhsc.edu; Melissa Brammer - mbrammer@tulane.edu; Karol Sestak - ksestak@tulane.edu; Ronald B Luftig - rlufti@lsuhsc.edu

* Corresponding author

Abstract

Dendritic cells (DC) are known to present exogenous protein Ag effectively to T cells. In this study we sought to identify the proteases that DC employ during antigen processing. The murine epidermal-derived DC line Xs52, when pulsed with PPD, optimally activated the PPD-reactive Th1 clone LNC.2F1 as well as the Th2 clone LNC.4k1, and this activation was completely blocked by chloroquine pretreatment. These results validate the capacity of XS52 DC to digest PPD into immunogenic peptides inducing antigen specific T cell immune responses. XS52 DC, as well as splenic DC and DCs derived from bone marrow degraded standard substrates for cathepsins B, C, D/E, H, J, and L, tryptase, and chymases, indicating that DC express a variety of protease activities. Treatment of XS52 DC with pepstatin A, an inhibitor of aspartic acid proteases, completely abrogated their capacity to present native PPD, but not trypsin-digested PPD fragments to Th1 and Th2 cell clones. Pepstatin A also inhibited cathepsin D/E activity selectively among the XS52 DC-associated protease activities. On the other hand, inhibitors of serine proteases (dichloroisocoumarin, DCI) or of cystein proteases (E-64) did not impair XS52 DC presentation of PPD, nor did they inhibit cathepsin D/E activity. Finally, all tested DC populations (XS52 DC, splenic DC, and bone marrow-derived DC) constitutively expressed cathepsin D mRNA. These results suggest that DC primarily employ cathepsin D (and perhaps E) to digest PPD into antigenic peptides.

Review

Dendritic cells (DC) are professional antigen presenting cells that induce primary antigen specific T cell responses [1] and exhibit all functional properties required to present exogenous antigen (Ag) to immunologically naïve T cells. These properties include: a) uptake of exogenous Ag via receptor-mediated endocytoses, b) processing of complex proteins into antigenic peptides, c) assembly of these peptides with MHC molecules, d) surface expression of MHC molecules as well as costimulatory molecules, including CD80, CD86, and CD40, e) secretion of T cell stimulatory cytokines, including IL-1β, IL-6, IL-8, TNF-α, and macrophage inflammatory protein (MIP)-1α and f) migration into draining lymph nodes [2].

Published: 02 August 2004

Received: 30 April 2004

doi:10.1186/1476-8518-2-8

© 2004 Mohamadzadeh et al; licensee BioMed Central Ltd.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the present study, we sought to characterize the Ag processing capacity of DC, as well as the enzymes previously involved in this process. In this regard, several groups have previously reported that epidermal LC and splenic DC, both of which contain small numbers of non-DC contaminants, exhibit significant Ag processing capacities [3-12]. LC freshly obtained from skin are quite potent in their Ag processing capacity, but the majority of these LC lose this capacity as they "mature" during subsequent culture [3-6,12]. On the other hand, other reports have shown that DC are less efficient than macrophages in Ag processing, with each employing different pathways for Ag processing [10,13-16]. These differences suggest the possibility of unique pathways and requirements for Ag presentation by DC.

With respect to the mechanisms by which DC process complex protein Ags, chloroquine has been shown to inhibit this process; this suggests that Ag processing primarily occurs within acidic compartments [6-8,10-12]. Macrophages and B cells have been reported to employ cathepsins B, D, and/or E for digesting protein Ag, including ovalbumin (OVA), hen egg white lysozyme (HEL), myoglobin, exogenous IgG, and Staphylococcus aureus nuclease [17-35]. These proteases may each exhibit differential pathways for activity; for example, macrophages appear to employ cathepsin D for the initial cleavage of myoglobin and cathepsin B for C-terminal trimming of resulting fragments [17]. Little information, however, has been available with respect to proteases that are employed by DC for Ag processing. Thus, in the present study we sought to identify the protease profiles produced by DC and then to identify which protease(s) would primarily mediate Ag processing in DC.

Materials and Methods

Cells

The XS52 DC cell line (a gift of Dr. Takashima, Dallas, Texas), a long-term DC line established from the epidermis of newborn BALB/c mice [23], were expanded in complete RPMI in the presence of 1 ng/ml murine rGM-CSF and 10% culture supernatants collected from the NS stromal cell line as described previously [23]. Other phenotypic and functional features of this line are described elsewhere [23-25]. As responding T cells, we used the protein purified derivative (PPD)-reactive Th1 clone LNC.2F1 and the Th2 clone LNC.4K1 [26], both of which were kindly provided by Dr. E. Schmitt (Institute for Immunology, Mainz, Germany). As control cells, we also employed Pam 212 keratinocytes [27], 7–17 dendritic epidermal T cells (DETC) [28], IJ774 macrophages (ATCC, Rockville, MD), and BW5147 thymoma cells (ATCC).

Splenic DC were purified from BALB/c mice (Jackson Laboratories, Bar Harbor, ME) by a series of magnetic bead separations as before [24,25]. Briefly, spleen cell suspensions were first depleted of B cells using Dynabeads conjugated with anti-mouse IgG. Subsequently, T cells were removed using beads coated with anti-CD4 (GK1.5) and anti-CD8 mAbs (3.155), and then macrophages were depleted using beads conjugated with F4/80 mAb. Finally, DC were positively sorted using beads coated with anti-DC mAb 4F7 [29]. The resulting preparations routinely contained >95% DC, as assessed by flow cytometry. DCs were propagated from bone marrow as described by Inaba et al. [30]. Using magnetic beads, bone marrow cell suspensions were first depleted of B cells (with anti-mouse IgG), I-A+ cells (with 2G9 mAb, Pharmingen, San Diego, CA), and T cells (with GK1.5 and 3.155 mAbs). The remaining I-A cells were then cultured in the presence of GM-CSF (10 ng/ml). The purity of bone marrow derived DC was more than 95% as determined by flow cytometry using anti-CD11c and anti-I-A antibody (not shown).

Determination of protease activities

Cells were lysed in 0.1% Triton X-100 in 0.9% NaCl; extracts were then examined for protease activities using the following substrates: a) Z-Arg-Arg-βNA (for cathepsin B, at pH 6.0), b) denatured hemoglobin (cathepsin D/E, pH 3.0), c) Arg-βNA (cathepsin H, pH 6.8), d) Z-Phe-Arg-MCA (cathepsin J, pH 7.5), e) Z-Phe-Arg-MCA (cathepsin L, pH 5.5), f) Gly-Phe-βNA (DPPI or cathepsin C, pH 5.5), g) BLT ester (BLT esterase, pH 7.5), and h) Suc-Ala-Ala-Pro-Phe-SBz and Suc-Phe-Leu-Phe-SBz (chymotrypsin-like proteases, pH 7.5). Samples were incubated at the indicated pH and enzymatic activities were assessed by colorimetric or fluorogenic changes [31]. Enzymatic activities were expressed as nmol/min/mg soluble protein, in which protein concentrations were measured by the bicinchoninic acid method using bovine serum albumin as a standard [32].

Ag presentation and T cell stimulation assays

XS52 DC were γ-irradiated (2000 rad) and then pulsed for 8 hr with 100 µg/ml of PPD (kindly provided by Dr. E. Schmitt, Mainz, Germany) in the presence of each of the following inhibitors (or vehicle controls): a) pepstatin A (100 µg/ml, Sigma, St. Louis, MO), b) DCI 100 µM, Sigma), c) E-64 (100 µM, Sigma), d) DMSO (1%), and e) NH4Cl (15 mM). Subsequently, the XS52 cells were washed 3 times with PBS to remove unbound PPD and then cultured in 96 round-bottom well-plates (104 cells/well) with either the PPD-reactive Th1 or Th2 clone (103 cells/well) in the presence of the same inhibitor at the above concentration. In some experiments, XS52 DC were pulsed overnight with PPD in the presence of an inhibitor and then fixed with 0.05% glutaraldehyde in PBS for 30 seconds at 4°C; the fixation reaction was stopped by adding 0.1 M L-lysine. These XS52 cells were then washed with PBS and examined for their ability to activate Th1 or
Th2 clones in the absence of protease inhibitors. In order to determine the mechanism of action for pepstatin A, XS52 cells were pulsed in its presence with PPD either in a native form or following digestion with trypsin-conjugated sepharose beads (Pierce, Rockford, IL) for 15 minutes at 37°C. We also examined the effect of added pepstatin A on the capacity of XS52 cells to activated allo- geneic T cells isolated from CBA mice (Jackson Laboratories). Samples were pulsed for 18 hr with 1 µCi of 3H-thymidine and then harvested using an automated cell harvester.

**RT-PCR Analysis**

mRNA expression for cathepsin D was examined by RT-PCR. RNA isolation, reverse-transcription, and cDNA amplification were carried out as previously described [33]. The following primers were designed based on the published sequence of murine cathepsin D [34]: 5’-GGT-CAGACGAGTTTCTGGG-3’ and 5’-GCTTAAAGCTTT-GCTCCTTTCGGG-3’. After 25 cycles of amplification, PCR products were analyzed in 1% agarose gel electrophoresis containing 2 µg/ml ethidium bromide. Other experimental conditions, including primer sequences for the β-actin control, are described elsewhere [33].

**Results**

**DC exhibit several different protease activities and they process the complex protein Ag PPD into antigenic peptides**

In the first set of experiments we sought to identify which protease activities were expressed by DC. A panel of synthetic peptide and protein substrates was incubated with extracts prepared from three DC populations: the XS52 DC line, 4F7+ splenic DC, and GM-CSF-propagated bone marrow DC. As noted in Table 1, each DC population exhibited all tested protease activities, including cathepsins B, C, D/E, H, J, and L, BLT esterase, and chymotrypsin-like proteases. Each protease activity in DC was substantially higher (up to 20 fold) than that detected in the BW5147 thymoma cell line, a line that expresses relatively low levels of protease activities. Moreover, cathepsin D/E activity was undetectable (<1 nmol/min/mg) in Pam 212 keratinocytes and 7–17 DETC (data not shown), indicating further cell type-specificity. These results demonstrate that DC produce a variety of protease activities and at relatively high levels.

We next asked whether DC are capable of digesting a complex protein Ag into antigenic products. In this regard, it has been reported previously that the original XS52 DC, as well as clones derived from this line, are capable of presenting KLH to the KLH-specific Th1 clone HDK-1 [23]. These results, however, did not fully test the processing capacity because it remained uncertain whether the conventional KLH preparation, which also contained many small molecular weight species, was indeed "processed" before effective presentation. For this reason, we developed a new experimental system using two PPD reactive T cell clones, a Th1 clone LNC.2F1 and a Th2 clone LNC.4K1. The advantage of PPD lies in the relative certainty of its purity. When pulsed with native PPD for 8 hr, XS52 DC were capable of stimulating both T cell clones effectively. In dose-response experiments (Fig 1A), XS52 DC induced maximal activation of both T cell clones at 25–100 µg/ml of PPD, whereas no significant activation was observed, even at higher concentrations, in the absence of XS52 DC (data not shown). Importantly, chloroquine (100 µM) inhibited completely the capacity of XS52 cells to activate both Th1 and Th2, T cell clones (Fig. 1B), indicating the requirement for processing of PPD in an acidic environment. These observations indicate that XS52 DC do possess the capacity to digest a complex protein Ag into an immunogenic Ag.

**Table 1: Protease Profiles Expressed by Several DC Populations**

| Protease          | XS52 DC | Splenic DC | Bone Marrow DC | BW5147 Thymoma Cells |
|-------------------|---------|------------|----------------|----------------------|
| Cathepsin B¹      | 133 ± 39² | 123 ± 3.3  | 121 ± 3.3      | 1.5 ± 0.08           |
| Cathepsin C       | 34 ± 7  | 16 ± 4     | 0.4 ± 0.1      | <0.01                |
| Cathepsin D/E     | 34 ± 6  | 30 ± 14    | 22 ± 2         | 1.6 ± 0.1            |
| Cathepsin H       | 2.8 ± 0.8 | 3.5 ± 0.7  | 1 ± 0.2        | 0.9 ± 0.2            |
| Cathepsin J       | 26 ± 0.3 | 0.7 ± 0.3  | 3.0 ± 0.1      | 0.2 ± 0.09           |
| Cathepsin L       | 14 ± 0.6 | 26 ± 11    | 19 ± 0.6       | 0.6 ± 0.08           |
| BLT esterase      | 25,000 ± 400 | 58,000 ± 4,000 | 21,300 ± 100 | <100               |
| Suc-FLF-SBz esterase | 1,900,000 ± 61,000 | 310,000 ± 10,800 | 1,150,000 ± 10,200 | 12,000 ± 100 |
| Suc-AAPFSBZ esterase | 433,000 ± 2,900 | 134,000 ± 7,300 | 360,000 ± 6,100 | 3,400 ± 600 |

¹Extracts prepared from the indicated cell types were examined for protease activities using a panel of standard substrates. ²Enzymatic activities are expressed as nmol/min/mg soluble protein. Data shown represent the mean ± SD from three independent preparations.
Pepstatin A inhibits the capacity of XS52 DC to present native PPD to T cells

To identify the proteases responsible for processing PPD, we employed three inhibitors: pepstatin A (aspartic acid protease inhibitor), DCI (serine protease inhibitor), and E-64 (cysteine protease inhibitor). XS52 DC were pulsed for 8 hr with native PPD in the presence of each inhibitor and then examined for the capacity to activate PPD-reactive Th1 and Th2 clones. To ensure a maximal effect, inhibitors were also added to cocultures of XS52 DC and T cells. As noted in Figure 2A, pepstatin A (100 µg/ml) almost completely blocked the capacity of XS52 cells to stimulate both T cell clones. When XS52 DC were pretreated with pepstatin A only during the 8 hr of Ag pulsing (but not during the subsequent coculture with T cells), we also observed significant, albeit less effective, inhibition (data not shown). By contrast, neither DCI nor E-64 caused any significant inhibition (Figure 2A). No inhibition was observed after treatment with 1% DMSO or 15 mM ammonium chloride alone, which was used to dissolve the above inhibitors. With respect to the mechanism of pepstatin A inhibition, the XS52 DC remained fully viable after 8 hr pre-incubation with pepstatin A (Figure 2B), thus excluding the possibility that pepstatin A had simply
killed the XS52 DC. When pepstatin A was added to XS52 DC that had been pulsed with PPD (100 µg/ml) and then fixed with paraformaldehyde, no inhibition was observed (Figure 3A). Moreover, pepstatin A failed to affect the capacity of XS52 DC to stimulate allogeneic T cells in a primary mixed lymphocyte reaction (Figure 3B); making it unlikely that pepstatin A had impaired the T cell-stimulatory capacity of XS52 DC. Finally, pepstatin A treatment was only effective when the native form of PPD was used as complex Ag, whereas it caused no inhibition when trypsin-digested PPD fragments were employed (Figure 3C). Based on these observations, we concluded that pepstatin A had primarily inhibited the processing events.

**Functional role of cathepsin D/E in the processing of PPD by XS52 DC**

To identify the protease(s) inhibited by pepstatin A, XS52 DC were pretreated for 1 hr with pepstatin A (100 µg/ml), and extracts prepared from these cells were then examined for enzymatic activities. As noted in Figure 4, 1 hr pretreatment with pepstatin A was sufficient to block cathepsin D/E activity significantly (>70%). Pepstatin A also inhibited,
albeit less effectively, cathepsin J activity and it had no significant effect on other tested protease activities. On the other hand, DCI and E64 were highly inhibitory of the chymotrypsin-like activities as well as cathepsin B, J, and/or L activities, but they did not inhibit cathepsin D/E. These results corroborate previous reports that pepstatin A inhibits cathepsin D/E activity relatively selectively [35]. Thus, it appears that cathepsin D/E is the primary target of pepstatin A, with the implication that these proteases play important roles in processing PPD by XS52 DC.

Cathepsins D and E are prototypic aspartic acid proteases, which exhibit maximal enzymatic activities at acidic pH. Because both digest denatured hemoglobin effectively, the substrate used to measure cathepsin D/E activity, and because both are equally susceptible to pepstatin A treatment, it remained uncertain where processing of PPD in

Figure 3
Failure of pepstatin A to inhibit the Ag presenting capacity of PPD-pulsed and fixed XS52 DC: (A) γ-irradiated XS52 DC were pulsed with PPD and then fixed with paraformaldehyde (left panels). Alternatively, XS52 DC were first fixed and then pulsed with PPD. Subsequently, the XS52 DC were cultured with the PPD-specific Th1 or Th2 clone in the presence or absence of pepstatin A. Data shown are the mean ± SD (n = 3) of 3H-thymidine uptake. (B): Allogeneic splenic T cells isolated from CBA mice (5 × 10⁵ cells/well) were cultured for 4 days with the indicated numbers of γ-irradiated XS52 DC in the presence or absence of pepstatin A. Data shown are the mean ± SD (n = 3) of 3H-thymidine uptake. (C): γ-irradiated XS52 DC were pulsed for 8 hr with either native PPD or trypsin-digested PPD in the presence or absence of pepstatin A. XS52 DC were then cocultured for 4 days with PPD-reactive Th1 or Th2 clones in the presence or absence of pepstatin A. Cocultures were then pulsed for 18 hr with 3H-thymidine and then harvested using a β-counter.
XS52 DC was mediated by cathepsin D, or cathepsin E, or both. As a first step to answer this question, we detected cathepsin D mRNA by RT-PCR in the XS52 DC line, as well as in 4F7+ splenic DC and a bone marrow derived DC line, indicating that DC do possess the capacity to produce cathepsin D (Figure 5).

**Conclusion**

The experiments reported in this study provide new information with respect to complex Ag processing by DC. First, the long-term DC line, XS52 DC, was capable of processing PPD into immunogenic peptides, in the complete absence of other cell types. Although previous studies using several different DC preparations have documented similar results (3–12), this is the first report validating the Ag processing capacity of DC, in the absence of contaminating cells. Second, we have characterized the protease profiles expressed by DC. XS52 DC, 4F7+ splenic DC, and bone marrow-derived DC, all exhibited significant protease activities for cathepsins B, C, D/E, H, J, and L, BLT esterase, and chymotrypsin. Thus, DC possess the capacity to produce a family of protease activities. Finally, pepstatin A, but not other protease inhibitors, abrogated almost completely the ability of XS52 DC to digest native PPD into an antigenic product, suggesting an important role for pepstatin A-sensitive proteases (most likely cathepsin D and/or E) during Ag processing by DC. Taken together, these results reinforce the concept that DC are fully capable of processing complex protein Ag into antigenic peptides.

**Figure 4**

**Pepstatin A Inhibits selectively the cathepsins D/E.** XS52 DC were pretreated for 60 min with each of protease inhibitors or vehicles. After extensive washing, the cells were extracted and subsequently examined for protease activities. Data shown are % inhibition compared with untreated control cells.
As described before, macrophages and B cells have been reported to employ cathepsins B, D, and E primarily to digest complex protein Ag, such as ovalbumin (OVA), hen egg white lysozyme (HEL), myoglobin, exogenous IgG, and Staphylococcus aureus nuclease (17–22). Here we report that DC also employ cathepsin D and/or E to digest PPD into an immunogenic Ag-product. This conclusion is supported by several lines of evidence: a) pepstatin A, but not other protease inhibitors, completely blocked the presentation of intact PPD by XS52 DC to PPD-reactive Th1 and Th2 clones, whereas it did not affect the presentation of PPD fragments; b) pepstatin A pretreatment inhibited cathepsin D/E activity selectively among the DC-associated protease activities; and c) all tested DC preparations expressed cathepsin D mRNA constitutively. In this regard, DC isolated from the mouse thoracic duct constitutively express cathepsin D mRNA. This is supported by several studies: 1) DC preparations tested and/or in the assays employed to detect cathepsin D. Nevertheless, our observations indicate that DC employ cathepsin D/E to degrade some protein Ag, with the implication that pepstatin A and other cathepsin D/E inhibitors [36] may be useful to prevent and even to treat unwanted hypersensitivity reactions against such protein Ag.

It is important to emphasize that different protein Ag may be degraded by different proteases in DC. Moreover, DC isolated from different tissues or in different maturational states may employ different proteases. For example, murine DC isolated from the thoracic are unable to digest human serum albumin effectively [14], and murine splenic DC purified following overnight culture have failed to degrade KLH significantly into a TCA-soluble form [13]. Moreover, several reports document that LC lose their Ag processing capacity as they mature in culture [3-6,12]. Thus, it will be interesting to compare DC from different tissues and in different states of maturation for their protease profiles and susceptibilities to pepstatin A treatment. We believe that the experimental system described in this report will provide unique opportunities to study the function of proteases and the regulation of their production in DC.

Competing Interests
None declared.

Author’s Contributions
Dr. Mohamadzadeh is the major contributor (15%) of the experimental data and a rough draft of the paper. The next three intermediate authors' contributed remaining data and advice. Dr. Luftig was the overall individual who directed the several drafts and contributed to providing a new set of references to the manuscript.

Acknowledgements
This work was supported by NIH grant DA016029 (MM) and Tulane base grant RR00164 (MM). The authors would like to thank Dr. M. J. McGuire (UTSMC, Dallas, Texas) for his support and the fruitful discussions.

References
1. Banchereau J, Steinman R: Dendritic cells and the control of immunity. Nature 1998, 392:245-247.
2. Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997, 9:10-15.
3. Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone A, Fathman C, Inaba K, Steinman R: Presentation of exogenous protein antigens by dendritic cells to T cell clones. J Exp Med 1989, 169:1169-1173.
4. Stossel H, Koch F, Kampgen E, Stoger P, Lenz A, Heufler C, Romani N, Schuler G: Disappearance of certain acidic organelles (endosomes and Langerhans cell granules) accompanies loss of antigen processing capacity upon culture of epidermal Langerhans cells. J Exp Med 1990, 172:1471-1479.
5. Pure E, Inaba K, Crowley M, Tardelli L, Witmer-Pack M, Ruberti G, Fathman G, Steinman R: Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain. J Exp Med 1990, 172:1459-1465.
6. Mohamadzadeh M, Pavlidou A, Enk A, Knop J, Rude E, Gradehansd G: Freshly isolated mouse 4F7+ splenic dendritic cells process and present exogenous antigens to T cells. Eur J Immunol 1994, 24:3170-3174.
12. Koch F, Trockenbacher B, Kämpgen E, Grauer O, Stössel H, Living-
10. Kapsenberg M, Teunissen M, Stiekema F, Keizer H:
9. Woods G, Henderson M, Qu M, Muller H:
8. Cohen P, Katz S:
7. Liu L, McPherson G: Antigen processing: cultured lymph-borne
dendritic cells can process and present native protein antigens. Immunology 1995, 84:241-247.
6. Cohen P, Katz S: Cultured human Langerhans cells process and present intact protein antigens. J Invest Dermatol 1992, 99:331-335.
5. Woods G, Henderson M, Qu M, Muller H: Processing of complex antigens and simple hapten-like molecules by epidermal Langerhans cells. J Leukoc Biol 1995, 57:891-896.
4. Kapsenberg M, Teunissen M, Stiekema F, Keizer H: Antigen-present-
ing cell function of dendritic cells and macrophages in proliferative T cell responses to soluble and particulate antigens. J Invest Immunol 1986, 16:345-348.
3. De Bruijn M, Nieland J, Harding C, Melief C: Processing and presen-
tation of intact hen egg-white lysozyme by dendritic cells. Eur J Immunol 1992, 22:2347-2351.
2. Koch F, Trockenbacher B, Kämpgen E, Grauer O, Stössel H, Living-
stone A, Schuler G, Romani N: Antigen processing in populations of mature murine dendritic cells is caused by subsets of incompletely matured cells. J Immunol 1995, 155:93-99.
1. Chain B, Kay P, Feldmann M: The cellular pathway of antigen presenta-
tion: Biochemical and functional analysis of antigen processing in dendritic cells and macrophages. Immunology 1986, 58:271-280.

Rhodes J, Andersen A: Role of cathepsin D in the degradation of human serum albumin by peritoneal macrophages and veiled cells in antigen presentation. Immunolett 1993, 37:101-110.

Hirot A, Masuyama N, Kurokina T, Fujita H, Himeno M, Tanaka Y: Analysis of post-lysosomal compartments. Biochem Biophys Res Commun 2004, 314:306-312.

Fonteneau JF, caravan GH, lrlvall M, Sanders C, Cover TL, Bhard-
woj N, Larsson M: Characterization of the MHCI class I cross-
presentation pathway for cell-associated antigens by human dendritic cells. Blood 2003, 102:4448-4455.

Noort J, Boon J, Van der Drift A, Wagenaar JP, Boots A, Boog CJ: Antigen processing by endosomal proteases determines which sites of sperm-whale myoglobin are eventually recognized by T cells. Eur J Immunol 1991, 21:1189-1996.

Williams K, Smith J: Isolation of a membrane associated cathe-
psin d-like enzyme from the model antigen presenting cell, A20, and its ability to generate antigenic fragments from a protein antigen in a cell-free system. Arch Biochem Biophys 1993, 305:298-306.

Rodriguez G, Diment S: Destructive proteolysis by cytokeine pro-
teases in antigen presentation of ovalbumin. J Immunol 1995, 25:1823-1830.

Van Noort H, Jacobs MJ: Cathepsin D, but not cathepsin B, releases T cell stimulatory fragments from lysozyme that are functional in the context of multiple murine classII MHC molecules. Eur J Immunol 1994, 24:2175-2181.

Rodriguez G, Diment S: Role of cathepsin D in antigen presen-
tation of ovalbumin. J Immunol 1992, 149:2894-2899.

Santoro L, Reboul A, Jornes A, Colomb MG: Major involvement of cathepsin B in the intracellular proteolytic processing of exogenous IgG in U937 Cells. Molecular Immunology 1993, 30:1033-1040.

Xu S, Arruzza K, Caceres-Dittmar G, Edelbaum D, Hashimoto K, Bergstresser PR, Takahshima A: Successive generation of antigen-presenting, dendritic cell lines from murine epidermis. J Immunol 1995, 154:2697-2703.

Mohamadzadeh M, Poltorak A, Bergstresser P, Beutler B, Takashima A: Dendritic cells produce macrophage inflammatory protein-1α, a new member of the CC chemokine family. J Immunol 1996, 156:3102-3107.

Mohamadzadeh M, Ariizumi K, Sugamura K, Bergstresser P, Takashima A: Expression of the common cytokine receptor γc chain by murine dendritic cell including epidermal Langerhans cells. Eur J Immunol 1996, 26:156-163.

Schmitt E, Brandwijk R, Snick J, Siebold B, Rüde E: TCGFIII/P40 is produced by naive murine CD4+ T cells but is not a general T cell growth factor. Eur J Immunol 1989, 19:2167-2172.

Yuspa S, Hawley-Nelson P, Koebler B, Stanley JR: A survey of transforma-
tion markers in differentiating epidermal cell lines in culture. Cancer Res 1980, 40:4694-4699.

Publish with BioMed Central and every scientist can read your work free of charge

*BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime.*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived in PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp